Seeking Alpha

Shire plc (SHPGY)

()

News & PR
Market Currents

Buzz
Twitter: SHPGY

Business Intelligence
Transcripts
Events
Key Developments

Instablog posts on SHPGY

Global Market Wrap: Equities Lower On Momentum Change by The LFB
TheLFB-Forex.com A Forex Trader PortalGlobal Market Wrap: Equities Lower On Momentum Change Equity Futures: Dow -24.00. S&P -3.00. NASDAQ -6.00. Japanese Nikkei +50.00. German Dax -11.00. European Trade: European shares turned negative around the opening bell in Thursday trade,... More »
December 17, 2009 • BAMXY.PK, SHPGY
Manufacturing issues persist, Lumizyme rejected again; downgrading recommendation from BUY to HOLD by Mark Mitchell
This is a follow up to this morning's post regarding the news that promising Pompe disease drug, Lumizyme, received a Complete Response Letter from the FDA. I defer the reader to that post for full details and analysis regarding my views on the Lumizyme Complete Response Letter... More »
November 16, 2009 • GENZ, SHPGY, PLX
New Data Ignites Investor Enthusiasm for Parkinson’s Disease by Michael Becker
In our August 2009 article titled “Treating Parkinson’s Disease: Investment Opportunities and Challenges,” we reviewed some of the historical challenges associated with developing treatments for Parkinson’s disease [PD] and cited reasons for optimism going forward in... More »
November 15, 2009 • IPXL, SRDX, BPAX
Friday's Rx-Recap for the Health Care Sector (10-30-09) by M. E. Garza
Below is a list of the companies that made news in the healthcare sector on Friday, October 30, 2009. This new list feature is meant to help investors keep tabs on the sector without having to scour through all the press releases. Biodel Inc. (Nasdaq:BIOD) announced Dr. Solomon Steiner, Chairman... More »
November 1, 2009 • ALNY, GERN, NVAX
Moving past earnings; focus is now on Lumizyme approval by Mark Mitchell
Genzyme (GENZ) released its Q3/09 financial results last week, with non-GAAP earnings coming up short of both mine and the markets expectations. Non-GAAP earnings were reported at $0.31 per share, significantly lower than my estimate ($0.39 per share) and the Street’s estimate ($0.44) for... More »
October 29, 2009 • GENZ, SHPGY, PLX
Trial setback is welcome news for Genzyme, but don't get too excited... by Mark Mitchell
Amicus Therapeutics (FOLD) announced that it's Gaucher disease drug candidate Plicera failed to demonstrate clinically meaningful improvements in key measures of disease in 17 of 18 patients who completed the open-label Phase II study. On a somewhat positive note, the... More »
October 5, 2009 • GENZ, SHPGY, PLX
Genzyme update highlights challenges with manufacturing biologics; reiterate near-term SELL by Mark Mitchell
Earlier today, Genzyme (GENZ) provided a manufacturing update with regard to the production of its blockbuster drug Cerezyme, and Fabrazyme; treatments for Gaucher disease and Fabry disease, respectively. The company reiterated that the it has sanitized and restarted the... More »
September 23, 2009 • GENZ, PLX, SHPGY
Nevermind Clolar; investors should remain focused on Cerezyme. Reiterate near-term SELL recommendation by Mark Mitchell
On Tuesday morning, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 9 to 3 against the label expansion of Genzyme's (GENZ) leukemia drug, Clolar, in acute myeloid leukemia (AML). The FDA does not have to follow this recommendation, however, it usually does, which suggests that the... More »
September 1, 2009 • GENZ, SHPGY, TEVA
Negative sentiment continues for Genzyme; reiterate near-term SELL recommendation by Mark Mitchell
Monday morning, it was announced that the FDA had approved a treatment protocol for Protalix BioTherapeutics' (PLX:AMEX) Phase III Gaucher disease therapy prGCD. This means that prGCD can be administered to Gaucher disease patients, particularly those affected by the shortage of... More »
August 17, 2009 • GENZ, SHPGY, PLX
Genzyme’s Manufacturing Disruption Highlights Investment Opportunities in Lysosomal Storage Disorders by Michael Becker
Proteins are essential components of the human body. They perform specific biological functions within a cell and each type of protein has a unique function. For example, enzymes are proteins that help biochemical reactions to occur within the body. But before they can carry out... More »
July 20, 2009 • GENZ, FOLD, CYTR

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Shire plc (SHPGY)

Instablog posts on SHPGY

Global Market Wrap: Equities Lower On Momentum Change by The LFB

Manufacturing issues persist, Lumizyme rejected again; downgrading recommendation from BUY to HOLD by Mark Mitchell

New Data Ignites Investor Enthusiasm for Parkinson’s Disease by Michael Becker

Friday's Rx-Recap for the Health Care Sector (10-30-09) by M. E. Garza

Moving past earnings; focus is now on Lumizyme approval by Mark Mitchell

Trial setback is welcome news for Genzyme, but don't get too excited... by Mark Mitchell

Genzyme update highlights challenges with manufacturing biologics; reiterate near-term SELL by Mark Mitchell

Nevermind Clolar; investors should remain focused on Cerezyme. Reiterate near-term SELL recommendation by Mark Mitchell

Negative sentiment continues for Genzyme; reiterate near-term SELL recommendation by Mark Mitchell

Genzyme’s Manufacturing Disruption Highlights Investment Opportunities in Lysosomal Storage Disorders by Michael Becker

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers